Generate QR code
Open Access
Subscription Access
Do we know everything about the KRAS gene?
https://doi.org/10.25557/2073-7998.2025.08.140-141
Abstract
The mutation status of MAPK-kinase signaling pathway genes plays an important role in anti-EGFR therapy. However not all tumors after diagnostics of RAS/BRAF genes have answered to anti-EGFR therapy. To search predictive markers for anti-EGFR therapy, 341 patients with colorectal cancer were examined. Frequent mutations in the KRAS, NRAS, and BRAF genes were detected in 200 (58.6 %) people. In addition, 4 rare mutations were detected. Also, it was found that the number of copies of the KRAS gene ≥ 9 is a predictive marker of resistance to anti-EGFR therapy.
Supporting agencies: The study was not supported by sponsorship
About the Authors
V. P. Shubin
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Vitaly P. Shubin
123423; 2, Salyama Adilya st.; Moscow
A. N. Loginova
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
123423; 2, Salyama Adilya st.; Moscow
S. I. Achkasov
Ryzhikh National Medical Research Center of Coloproctology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
123423; 2, Salyama Adilya st.; 125993; 2/1, Barrikadnaya st.; Moscow
Yu. A. Shelygin
Ryzhikh National Medical Research Center of Coloproctology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
123423; 2, Salyama Adilya st.; 125993; 2/1, Barrikadnaya st.; Moscow
A. S. Tsukanov
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
123423; 2, Salyama Adilya st.; Moscow
References
1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2023 godu. [The state of oncological care for the population of Russia in 2023]. Moscow: P.A. Herzen Moscow Oncology Research Institute − branch of the Federal State Budgetary Institution «NMITs of Radiology» of the Ministry of Health of Russia. 2024. – 262 p. (In Russ.)
2. Bou Antoun N., Chioni A.-M. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences. 2023;24(15):12222.
3. Shubin V.P., Achkasov S.I., Shelygin Y.A. et al. Vliyaniye variatsii chisla kopiy gena KRAS na rezul’taty targetnoy terapii kolorektal’nogo raka [Correlation of the KRAS gene’s copy number variation and the results of targeted therapy for colorectal cancer]. Koloproktologia [Coloproctology]. 2024;23(4):10–16. (In Russ.). doi: 10.33878/2073-7556-2024-23-4-10-16
Review
For citations:
Shubin V.P., Loginova A.N., Achkasov S.I., Shelygin Yu.A., Tsukanov A.S. Do we know everything about the KRAS gene? Medical Genetics. 2025;24(8):140-141. (In Russ.) https://doi.org/10.25557/2073-7998.2025.08.140-141
Views:
29
Email this article 